[{"command":"settings","settings":{"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"entitySetting":{"type":"bibcite_reference","bundle":"journal_article","mapping":{"node":{"blog":"blog","class":"classes","events":"calendar","faq":"faq","link":"links","news":"news","page":"","person":"people","presentation":"presentations","software_project":"software","software_release":"software"},"bibcite_reference":{"*":"publications"},"paragraph":{"class_material":"classes"}},"viewmode":"teaser"},"user":{"uid":0,"permissionsHash":"562870491b50c3fc24e6e0b0fe1b47a750333b0e6611a9dc369ac6282f4e2f5e"}},"merge":true},{"command":"add_js","selector":"body","data":[{"src":"\/files\/js\/js_dUutw8KU0b_VTfeeKNtXxuufrdu4hJi0Wu4hkGI2cos.js?scope=footer\u0026delta=0\u0026language=en\u0026theme=zen_lab_aecm\u0026include=eJzLL44vKE3KyUxOLMnMzyvWTykqLUjM0ctHFdbLzSxO1ikrzixJ1U_OzytJrSgpTcxxK83JCctMLQcAsjEbVw"}]},{"command":"insert","method":"replaceWith","selector":"#","data":"\n  \u003Cdiv class=\u0022field field--name-field-widget-title field--type-string field--label-visually_hidden field--mode-full\u0022\u003E\n    \u003Cdiv class=\u0022field--label sr-only\u0022\u003EWidget Title\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003EPI Publications\u003C\/div\u003E\n          \u003C\/div\u003E\n\n\u003Cul  id=\u0022list-of-posts\u0022 more_link_id=\u0022node-readmore\u0022 class=\u0022publications view-teaser list-view\u0022\u003E\n \u003Cli\u003E\n\u003Carticle class=\u0022bibcite-reference bibcite bibcite--teaser\u0022\u003E\n  \n  \n\n  \u003Cdiv class=\u0022bibcite__content\u0022\u003E\n    \n    \n            \u003Cdiv class=\u0022field field--name-field-publication-media field--type-entity-reference field--label-hidden field--mode-teaser field--item\u0022\u003E\u003Cdiv class=\u0022media media--type-image media--view-mode-medium\u0022\u003E\n  \n  \n            \u003Cdiv data-quickedit-entity-id=\u0022media\/835\u0022 class=\u0022field field--name-field-media-image field--type-image field--label-hidden field--mode-medium field--item\u0022\u003E    \u003Cpicture\u003E\n                  \u003Csource srcset=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=Clic_4iu 1x, \/files\/styles\/width_600\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=BFHu0HkM 2x\u0022 media=\u0022(min-width: 768px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n              \u003Csource srcset=\u0022\/files\/styles\/width_240\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=1NMngflv 1x, \/files\/styles\/width_480\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=wfsYt-g9 2x\u0022 media=\u0022(min-width: 0px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n                  \u003Cimg loading=\u0022lazy\u0022 src=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=Clic_4iu\u0022 alt=\u0022Biochemical Pharmacology\u0022 class=\u0022img-responsive\u0022 \/\u003E\n\n  \u003C\/picture\u003E\n\n\u003C\/div\u003E\n      \n\u003C\/div\u003E\n\u003C\/div\u003E\n      \u003Cdiv class=\u0022bibcite-citation\u0022\u003E\n      \u003Cdiv class=\u0022csl-bib-body\u0022\u003E\u003Cdiv class=\u0022csl-entry\u0022\u003E\u003Cdiv class=\u0022csl-right-inline\u0022\u003EThielen N, Kuang C, Chu E, Wei N. \u003Ca href=\u0022\/kuang-lab\/publications\/high-throughput-screening-novel-drug-combinations-using-patient-derived-organoids\u0022 hreflang=\u0022en\u0022\u003EHigh-throughput screening for novel drug combinations using patient-derived organoids\u003C\/a\u003E. \u003Ci\u003EBiochemical Pharmacology\u003C\/i\u003E. Published online 2026.\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n  \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-publishers-version field--type-link field--label-visually_hidden field--mode-teaser\u0022\u003E\n    \u003Cdiv class=\u0022field--label sr-only\u0022\u003EPublisher\u0027s Version\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006295226004259\u0022\u003EPublisher Site Link\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n                \u003Cdiv class=\u0022field--label field--abstract\u0022\u003E\n      \u003Cbutton class=\u0022btn-abstract collapsed\u0022 data-toggle=\u0022collapse\u0022 data-target=\u0022#collapseAbstract\u0022 aria-expanded=\u0022false\u0022 aria-controls=\u0022collapseAbstract\u0022\u003EAbstract \u003C\/button\u003E\n    \u003C\/div\u003E\n                  \u003Cdiv class=\u0022field--item abstract--content collapse\u0022 id=\u0022collapseAbstract\u0022 aria-expanded=\u0026quot;false\u0026quot;\u003E\u003Cp\u003EPatient-Derived Organoids (PDO) are 3D culture systems that mimic human tissues more accurately than traditional 2D cell lines. They maintain cellular diversity, spatial layout, and patient-specific traits, making them essential for high-throughput screening (HTS). Due to tumor heterogeneity and cancer therapies resistance, combination screening has become increasingly important. Moreover, recent advancements now enable larger-scale combination studies. Standardized matrices improve uniformity and reproducibility, while smaller plate formats and automation streamline seeding, dosing, and overall workflow. Microfluidic systems add further flexibility by enabling precise concentration gradients and sequential treatment delivery, expanding the range of possible combination designs. Meanwhile, assay readouts now extend well beyond viability as a single endpoint. Label free imaging, quantitative morphology, growth dynamics, and lineage related features now provide more sensitive and informative measures of both cytostatic and cytotoxic responses across organoid models. Diverse analytics are essential for understanding combination responses. Dose-response metrics and growth rate-adjusted parameters consider differences in baseline growth, while established combination calculations provide visualized ways to measure synergy across complex dose matrices. This comprehensive review synthesizes current knowledge on PDO-based HTS, with emphasis on technological strategies for adapting PDOs to screening platforms; design considerations for combination screening; analytical methodologies and readout technologies; challenge and limitation of PDO-based HTS and future development. Taken together, PDO-based HTS can be a powerful approach for identifying and refining therapeutic combinations. Ongoing progress in assay standardization, automation, micro-engineered delivery, and integrated analysis will improve the discovery of effective and applicable combination treatments, accelerate translation into precision medicine.\u003C\/p\u003E\u003C\/div\u003E\n        \n  \u003C\/div\u003E\n\u003C\/article\u003E\n\u003C\/li\u003E\n \u003Cli\u003E\n\u003Carticle class=\u0022bibcite-reference bibcite bibcite--teaser\u0022\u003E\n  \n  \n\n  \u003Cdiv class=\u0022bibcite__content\u0022\u003E\n    \n    \n            \u003Cdiv class=\u0022field field--name-field-publication-media field--type-entity-reference field--label-hidden field--mode-teaser field--item\u0022\u003E\u003Cdiv class=\u0022media media--type-image media--view-mode-medium\u0022\u003E\n  \n  \n            \u003Cdiv data-quickedit-entity-id=\u0022media\/833\u0022 class=\u0022field field--name-field-media-image field--type-image field--label-hidden field--mode-medium field--item\u0022\u003E    \u003Cpicture\u003E\n                  \u003Csource srcset=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.webp?itok=CyjzjfNQ 1x, \/files\/styles\/width_600\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.webp?itok=kut_0KrK 2x\u0022 media=\u0022(min-width: 768px)\u0022 type=\u0022image\/webp\u0022\/\u003E\n              \u003Csource srcset=\u0022\/files\/styles\/width_240\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.webp?itok=fsBwec1H 1x, \/files\/styles\/width_480\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.webp?itok=TuQ9rzxf 2x\u0022 media=\u0022(min-width: 0px)\u0022 type=\u0022image\/webp\u0022\/\u003E\n              \u003Csource srcset=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.jpeg?itok=CyjzjfNQ 1x, \/files\/styles\/width_600\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.jpeg?itok=kut_0KrK 2x\u0022 media=\u0022(min-width: 768px)\u0022 type=\u0022image\/jpeg\u0022\/\u003E\n              \u003Csource srcset=\u0022\/files\/styles\/width_240\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.jpeg?itok=fsBwec1H 1x, \/files\/styles\/width_480\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.jpeg?itok=TuQ9rzxf 2x\u0022 media=\u0022(min-width: 0px)\u0022 type=\u0022image\/jpeg\u0022\/\u003E\n                  \u003Cimg loading=\u0022lazy\u0022 src=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/m_jnci_117_1cover.jpeg?itok=CyjzjfNQ\u0022 alt=\u0022JNCI Cover\u0022 class=\u0022img-responsive\u0022 \/\u003E\n\n  \u003C\/picture\u003E\n\n\u003C\/div\u003E\n      \n\u003C\/div\u003E\n\u003C\/div\u003E\n      \u003Cdiv class=\u0022bibcite-citation\u0022\u003E\n      \u003Cdiv class=\u0022csl-bib-body\u0022\u003E\u003Cdiv class=\u0022csl-entry\u0022\u003E\u003Cdiv class=\u0022csl-right-inline\u0022\u003ECheng E, Ou FS, Gatten C, et al. \u003Ca href=\u0022\/kuang-lab\/publications\/plant-based-diet-and-survival-among-patients-metastatic-colorectal-cancer\u0022 hreflang=\u0022en\u0022\u003EPlant-based diet and survival among patients with metastatic colorectal cancer.\u003C\/a\u003E. \u003Ci\u003EJournal of the National Cancer Institute\u003C\/i\u003E. 2025;117(1):169-179. doi:10.1093\/jnci\/djae213\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n  \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-publishers-version field--type-link field--label-visually_hidden field--mode-teaser\u0022\u003E\n    \u003Cdiv class=\u0022field--label sr-only\u0022\u003EPublisher\u0027s Version\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/academic.oup.com\/jnci\/article\/117\/1\/169\/7745818\u0022\u003EPublisher Site Link\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n                \u003Cdiv class=\u0022field--label field--abstract\u0022\u003E\n      \u003Cbutton class=\u0022btn-abstract collapsed\u0022 data-toggle=\u0022collapse\u0022 data-target=\u0022#collapseAbstract\u0022 aria-expanded=\u0022false\u0022 aria-controls=\u0022collapseAbstract\u0022\u003EAbstract \u003C\/button\u003E\n    \u003C\/div\u003E\n                  \u003Cdiv class=\u0022field--item abstract--content collapse\u0022 id=\u0022collapseAbstract\u0022 aria-expanded=\u0026quot;false\u0026quot;\u003E\u003Cp\u003E\u003Cb\u003EBACKGROUND: \u003C\/b\u003EA plant-based diet is associated with better survival among patients with nonmetastatic colorectal cancer (CRC), but its association in metastatic CRC is unknown.\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cb\u003EMETHODS: \u003C\/b\u003EUsing an National Cancer Institute-sponsored trial (CALGB\/SWOG 80405), we included 1284 patients who completed validated food frequency questionnaires at the initiation of metastatic CRC treatment. We calculated 3 indices: overall plant-based diet index (PDI), which emphasized consumption of all plant foods while reducing animal food intake; healthful plant-based diet index (hPDI), which emphasized consumption of healthful plant foods such as whole grains, fruits, and vegetables; and unhealthful plant-based diet index (uPDI), which emphasized consumption of less healthful plant foods such as fruit juices, refined grains, and sugar-sweetened beverages. We estimated the associations of 3 indices (quintiles) with overall survival (OS) and progression-free survival (PFS) using multivariable Cox proportional hazards regression.\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cb\u003ERESULTS: \u003C\/b\u003EWe observed 1100 deaths and 1204 progression events (median follow-up = 6.1\u2009years). Compared with the lowest quintile, patients in the highest quintile of PDI had significantly better survival (hazard ratio [HR] for OS = 0.76 [0.62-0.94], Ptrend\u2009=\u2009.004; PFS = 0.81 [0.66-0.99], Ptrend\u2009=\u2009.09). Similar findings were observed for hPDI (HR for OS = 0.81 [0.65-1.01], Ptrend\u2009=\u2009.053; PFS = 0.80 [0.65-0.98], Ptrend\u2009=\u2009.04), whereas uPDI was not associated with worse survival (HR for OS = 1.16 [0.94-1.43], Ptrend\u2009=\u2009.21; PFS = 1.12 [0.92-1.36], Ptrend\u2009=\u2009.42).\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cb\u003ECONCLUSIONS: \u003C\/b\u003EOur study suggests that a plant-based diet, especially when rich in healthful plant foods, is associated with better survival among patients with metastatic CRC. The cause of survival benefits warrants further investigation.\u003C\/p\u003E\n\u003C\/div\u003E\n        \n  \u003C\/div\u003E\n\u003C\/article\u003E\n\u003C\/li\u003E\n \u003Cli\u003E\n\u003Carticle class=\u0022bibcite-reference bibcite bibcite--teaser\u0022\u003E\n  \n  \n\n  \u003Cdiv class=\u0022bibcite__content\u0022\u003E\n    \n    \n            \u003Cdiv class=\u0022field field--name-field-publication-media field--type-entity-reference field--label-hidden field--mode-teaser field--item\u0022\u003E\u003Cdiv class=\u0022media media--type-image media--view-mode-medium\u0022\u003E\n  \n  \n            \u003Cdiv data-quickedit-entity-id=\u0022media\/835\u0022 class=\u0022field field--name-field-media-image field--type-image field--label-hidden field--mode-medium field--item\u0022\u003E    \u003Cpicture\u003E\n                  \u003Csource srcset=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=Clic_4iu 1x, \/files\/styles\/width_600\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=BFHu0HkM 2x\u0022 media=\u0022(min-width: 768px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n              \u003Csource srcset=\u0022\/files\/styles\/width_240\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=1NMngflv 1x, \/files\/styles\/width_480\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=wfsYt-g9 2x\u0022 media=\u0022(min-width: 0px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n                  \u003Cimg loading=\u0022lazy\u0022 src=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s0006295224x00106-cov150h.gif?itok=Clic_4iu\u0022 alt=\u0022Biochemical Pharmacology\u0022 class=\u0022img-responsive\u0022 \/\u003E\n\n  \u003C\/picture\u003E\n\n\u003C\/div\u003E\n      \n\u003C\/div\u003E\n\u003C\/div\u003E\n      \u003Cdiv class=\u0022bibcite-citation\u0022\u003E\n      \u003Cdiv class=\u0022csl-bib-body\u0022\u003E\u003Cdiv class=\u0022csl-entry\u0022\u003E\u003Cdiv class=\u0022csl-right-inline\u0022\u003EMo C, Wei N, Li T, Bhat MA, Mohammadi M, Kuang C. \u003Ca href=\u0022\/kuang-lab\/publications\/cdk9-inhibitors-treatment-solid-tumors\u0022 hreflang=\u0022en\u0022\u003ECDK9 inhibitors for the treatment of solid tumors.\u003C\/a\u003E. \u003Ci\u003EBiochemical pharmacology\u003C\/i\u003E. 2024;229:116470. doi:10.1016\/j.bcp.2024.116470\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n  \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-publishers-version field--type-link field--label-visually_hidden field--mode-teaser\u0022\u003E\n    \u003Cdiv class=\u0022field--label sr-only\u0022\u003EPublisher\u0027s Version\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006295224004532\u0022\u003EPublisher Site Link\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n                \u003Cdiv class=\u0022field--label field--abstract\u0022\u003E\n      \u003Cbutton class=\u0022btn-abstract collapsed\u0022 data-toggle=\u0022collapse\u0022 data-target=\u0022#collapseAbstract\u0022 aria-expanded=\u0022false\u0022 aria-controls=\u0022collapseAbstract\u0022\u003EAbstract \u003C\/button\u003E\n    \u003C\/div\u003E\n                  \u003Cdiv class=\u0022field--item abstract--content collapse\u0022 id=\u0022collapseAbstract\u0022 aria-expanded=\u0026quot;false\u0026quot;\u003E\u003Cp\u003ECyclin-dependent kinase 9 (CDK9) regulates mRNA transcription by promoting RNA Pol II elongation. CDK9 is now emerging as a potential therapeutic target for cancer, since its overexpression has been found to correlate with cancer development and worse clinical outcomes. While much work on CDK9 inhibition has focused on hematologic malignancies, the role of this cancer driver in solid tumors is starting to come into focus. Many solid cancers also overexpress CDK9 and depend on its activity to promote downstream oncogenic signaling pathways. In this review, we summarize the latest knowledge of CDK9 biology in solid tumors and the studies of small molecule CDK9 inhibitors. We discuss the results of the latest clinical trials of CDK9 inhibitors in solid tumors, with a focus on key issues to consider for improving the therapeutic impact of this drug class.\u003C\/p\u003E\n\u003C\/div\u003E\n        \n  \u003C\/div\u003E\n\u003C\/article\u003E\n\u003C\/li\u003E\n \u003Cli\u003E\n\u003Carticle class=\u0022bibcite-reference bibcite bibcite--teaser\u0022\u003E\n  \n  \n\n  \u003Cdiv class=\u0022bibcite__content\u0022\u003E\n    \n    \n            \u003Cdiv class=\u0022field field--name-field-publication-media field--type-entity-reference field--label-hidden field--mode-teaser field--item\u0022\u003E\u003Cdiv class=\u0022media media--type-image media--view-mode-medium\u0022\u003E\n  \n  \n            \u003Cdiv data-quickedit-entity-id=\u0022media\/836\u0022 class=\u0022field field--name-field-media-image field--type-image field--label-hidden field--mode-medium field--item\u0022\u003E    \u003Cpicture\u003E\n                  \u003Csource srcset=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s1040842824x00086-cov150h.gif?itok=H2WLj5fy 1x, \/files\/styles\/width_600\/public\/kuang-lab\/files\/images\/1-s2.0-s1040842824x00086-cov150h.gif?itok=Z_uVjFV7 2x\u0022 media=\u0022(min-width: 768px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n              \u003Csource srcset=\u0022\/files\/styles\/width_240\/public\/kuang-lab\/files\/images\/1-s2.0-s1040842824x00086-cov150h.gif?itok=X6mDWQFw 1x, \/files\/styles\/width_480\/public\/kuang-lab\/files\/images\/1-s2.0-s1040842824x00086-cov150h.gif?itok=nS28_Ble 2x\u0022 media=\u0022(min-width: 0px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n                  \u003Cimg loading=\u0022lazy\u0022 src=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s1040842824x00086-cov150h.gif?itok=H2WLj5fy\u0022 alt=\u0022Critical Review Oncology Hematology\u0022 class=\u0022img-responsive\u0022 \/\u003E\n\n  \u003C\/picture\u003E\n\n\u003C\/div\u003E\n      \n\u003C\/div\u003E\n\u003C\/div\u003E\n      \u003Cdiv class=\u0022bibcite-citation\u0022\u003E\n      \u003Cdiv class=\u0022csl-bib-body\u0022\u003E\u003Cdiv class=\u0022csl-entry\u0022\u003E\u003Cdiv class=\u0022csl-right-inline\u0022\u003EChen BS, Chan SY, Bteich F, Kuang C, Meyerhardt JA, Ma KSK. \u003Ca href=\u0022\/kuang-lab\/publications\/safety-and-efficacy-liposomal-irinotecan-second-line-treatment-advanced-pancreatic\u0022 hreflang=\u0022en\u0022\u003ESafety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis.\u003C\/a\u003E. \u003Ci\u003ECritical reviews in oncology\/hematology\u003C\/i\u003E. 2024;201:104386. doi:10.1016\/j.critrevonc.2024.104386\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n  \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-publishers-version field--type-link field--label-visually_hidden field--mode-teaser\u0022\u003E\n    \u003Cdiv class=\u0022field--label sr-only\u0022\u003EPublisher\u0027s Version\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.sciencedirect.com\/science\/article\/pii\/S104084282400129X\u0022\u003EPublisher Site Link\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n                \u003Cdiv class=\u0022field--label field--abstract\u0022\u003E\n      \u003Cbutton class=\u0022btn-abstract collapsed\u0022 data-toggle=\u0022collapse\u0022 data-target=\u0022#collapseAbstract\u0022 aria-expanded=\u0022false\u0022 aria-controls=\u0022collapseAbstract\u0022\u003EAbstract \u003C\/button\u003E\n    \u003C\/div\u003E\n                  \u003Cdiv class=\u0022field--item abstract--content collapse\u0022 id=\u0022collapseAbstract\u0022 aria-expanded=\u0026quot;false\u0026quot;\u003E\u003Cp\u003E\u003Cb\u003EINTRODUCTION: \u003C\/b\u003ENanoliposomal irinotecan (nal-IRI) is a novel regimen for pancreatic cancer, featuring a longer half-life and an increased area under the concentration-time curve. This study aims to assess the safety and efficacy of nal-IRI as a second-line treatment for advanced pancreatic cancer.\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cb\u003EMETHODS: \u003C\/b\u003EA systemic literature search was conducted based on articles published before September 26th, 2023 in databases, including PubMed, Cochrane Library, EMBASE and Web of Science. The fixed effects model was used to calculate the pooled mean difference for overall survival (OS) and progression-free survival (PFS), as well as the pooled odds ratio for the overall response rate (ORR) and the risk of adverse events.\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cb\u003ERESULTS: \u003C\/b\u003EA total of 21 studies, including 3044 patients with locally advanced unresectable or metastatic pancreatic cancers, were considered eligible. The use of nal-IRI, combined with 5-fluorouracil and leucovorin, resulted in significantly improved PFS (pooled mean difference=1.01 months, 95\u202f% confidence interval [CI]=0.97-1.05, p\u0026lt;0.01) and OS (pooled mean difference=0.29 months, 95\u202f%CI=0.18-0.39, p\u0026lt;0.01), as well as significantly better ORR (pooled odds ratio=2.06, 95\u202f%CI=1.30-3.27, p=0.002) compared to other second-line regimens. Nonetheless, an increased risk of grade 3 or greater neutropenia, anemia, hypokalemia, diarrhea, and vomiting was also noted.\u003C\/p\u003E\n\n\u003Cp\u003E\u003Cb\u003ECONCLUSION: \u003C\/b\u003ESecond-line treatments based on nal-IRI exhibited significantly improved PFS, OS, and ORR compared to other available treatments in advanced pancreatic cancer. Further research is necessary to corroborate these findings and define the role of nal-IRI in both first and later lines of therapy.\u003C\/p\u003E\n\u003C\/div\u003E\n        \n  \u003C\/div\u003E\n\u003C\/article\u003E\n\u003C\/li\u003E\n \u003Cli\u003E\n\u003Carticle class=\u0022bibcite-reference bibcite bibcite--teaser\u0022\u003E\n  \n  \n\n  \u003Cdiv class=\u0022bibcite__content\u0022\u003E\n    \n    \n            \u003Cdiv class=\u0022field field--name-field-publication-media field--type-entity-reference field--label-hidden field--mode-teaser field--item\u0022\u003E\u003Cdiv class=\u0022media media--type-image media--view-mode-medium\u0022\u003E\n  \n  \n            \u003Cdiv data-quickedit-entity-id=\u0022media\/834\u0022 class=\u0022field field--name-field-media-image field--type-image field--label-hidden field--mode-medium field--item\u0022\u003E    \u003Cpicture\u003E\n                  \u003Csource srcset=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s1533002824x00055-cov150h.gif?itok=6g1Rk-xq 1x, \/files\/styles\/width_600\/public\/kuang-lab\/files\/images\/1-s2.0-s1533002824x00055-cov150h.gif?itok=FrKY2Kqj 2x\u0022 media=\u0022(min-width: 768px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n              \u003Csource srcset=\u0022\/files\/styles\/width_240\/public\/kuang-lab\/files\/images\/1-s2.0-s1533002824x00055-cov150h.gif?itok=TramIRVQ 1x, \/files\/styles\/width_480\/public\/kuang-lab\/files\/images\/1-s2.0-s1533002824x00055-cov150h.gif?itok=iFcB8faN 2x\u0022 media=\u0022(min-width: 0px)\u0022 type=\u0022image\/gif\u0022\/\u003E\n                  \u003Cimg loading=\u0022lazy\u0022 src=\u0022\/files\/styles\/width_300\/public\/kuang-lab\/files\/images\/1-s2.0-s1533002824x00055-cov150h.gif?itok=6g1Rk-xq\u0022 alt=\u0022Clinical Colorectal Cancer\u0022 class=\u0022img-responsive\u0022 \/\u003E\n\n  \u003C\/picture\u003E\n\n\u003C\/div\u003E\n      \n\u003C\/div\u003E\n\u003C\/div\u003E\n      \u003Cdiv class=\u0022bibcite-citation\u0022\u003E\n      \u003Cdiv class=\u0022csl-bib-body\u0022\u003E\u003Cdiv class=\u0022csl-entry\u0022\u003E\u003Cdiv class=\u0022csl-right-inline\u0022\u003EMo C, Chadha B, Kuang C. \u003Ca href=\u0022\/kuang-lab\/publications\/evolving-landscape-new-therapies-metastatic-colorectal-cancer\u0022 hreflang=\u0022en\u0022\u003EAn Evolving Landscape: New Therapies for Metastatic Colorectal Cancer.\u003C\/a\u003E. \u003Ci\u003EClinical colorectal cancer\u003C\/i\u003E. 2024;23(4):337-345. doi:10.1016\/j.clcc.2024.08.003\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n  \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-publishers-version field--type-link field--label-visually_hidden field--mode-teaser\u0022\u003E\n    \u003Cdiv class=\u0022field--label sr-only\u0022\u003EPublisher\u0027s Version\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1533002824000768\u0022\u003EPublisher Site Link\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n                \u003Cdiv class=\u0022field--label field--abstract\u0022\u003E\n      \u003Cbutton class=\u0022btn-abstract collapsed\u0022 data-toggle=\u0022collapse\u0022 data-target=\u0022#collapseAbstract\u0022 aria-expanded=\u0022false\u0022 aria-controls=\u0022collapseAbstract\u0022\u003EAbstract \u003C\/button\u003E\n    \u003C\/div\u003E\n                  \u003Cdiv class=\u0022field--item abstract--content collapse\u0022 id=\u0022collapseAbstract\u0022 aria-expanded=\u0026quot;false\u0026quot;\u003E\u003Cp\u003ESubstantial progress is being made in the development of novel therapies directed against colorectal cancer. The discovery of various molecular markers and advances in tumor profiling have facilitated the development of new targeted agents and immunotherapy. Not only have these drugs improved progression-free survival and even overall survival in some cases, but their related outcomes have also raised questions as to how to best combine or sequence therapies for even greater efficacy. Furthermore, we are beginning to understand how these combination therapies may yield for greater therapeutic response for patients with microsatellite stable colorectal cancer for which there is much need for improvement. In this article, we review recent trial data and explore the outcomes of various targeted therapies and immunotherapies for patient with advanced colorectal cancer.\u003C\/p\u003E\n\u003C\/div\u003E\n        \n  \u003C\/div\u003E\n\u003C\/article\u003E\n\u003C\/li\u003E\n\u003C\/ul\u003E\n  \u003Cnav role=\u0022navigation\u0022 aria-labelledby=\u0022pagination-for-pi-publications\u0022 id=pager-heading\u003E\n    \u003Ch3 id=\u0022pagination-for-pi-publications\u0022 class=\u0022visually-hidden\u0022\u003Epagination for pi publications\u003C\/h3\u003E\n    \u003Cul class=\u0022js-pager__items pager-mini\u0022\u003E\n            \u003Cli class=\u0022current\u0022\u003E\n        \u003Cspan aria-live=\u0022polite\u0022\u003E\n            \u003Cspan class=\u0022visually-hidden\u0022\u003EPI Publications\u003C\/span\u003E\n            1 of 3\n          \u003C\/span\u003E      \u003C\/li\u003E\n              \u003Cli\u003E\n          \u003Ca href=\u0022\/kuang-lab\/refresh-widget-content\/2196?page=1\u0026amp;selector=list-of-posts\u0026amp;pagerid=pager-heading\u0026amp;moreid=node-readmore\u0022 class=\u0022use-ajax next\u0022 rel=\u0022next\u0022\u003E\u003Cspan aria-hidden=\u0022true\u0022\u003E\u203a\u203a\u003C\/span\u003E\u003Cspan class=\u0022visually-hidden\u0022\u003ENext page\u003C\/span\u003E\u003C\/a\u003E\n        \u003C\/li\u003E\n          \u003C\/ul\u003E\n  \u003C\/nav\u003E\n\n\u003Cdiv class=\u0022node-readmore\u0022 id=node-readmore\u003E\u003C\/div\u003E\n","settings":null},{"command":"insert","method":"replaceWith","selector":"#","data":"","settings":null},{"command":"insert","method":"replaceWith","selector":"#","data":"","settings":null},{"command":"insert","method":"replaceWith","selector":".field--name-field-widget-title","data":"","settings":null}]